Patents by Inventor Aya Jakobovits

Aya Jakobovits has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acids and corresponding proteins entitled 282P1G3 useful in treatment and detection of cancer
    Publication number: 20070059729
    Abstract: A novel gene 282P1G3 and its encoded protein, and variants thereof, are described wherein 282P1G3 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 282P1G3 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 282P1G3 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 282P1G3 can be used in active or passive immunization.
    Type: Application
    Filed: May 23, 2006
    Publication date: March 15, 2007
    Applicant: AGENSYS, INC.
    Inventors: Mary Faris, Pia Challita-Eid, Aya Jakobovits, Arthur Raitano, Wangmao Ge
  • 84P2A9: a prostate and testis specific protein highly expressed in prostate cancer
    Publication number: 20070054363
    Abstract: A novel gene (designated 84P2A9) and its encoded protein is described. While 84P2A9 exhibits prostate and testis specific expression in normal adult tissue, it is aberrantly expressed multiple cancers including prostate, testis, kidney, brain, bone, skin, ovarian, breast, pancreas, colon, lymphocytic and lung cancers. Consequently, 84P2A9 provides a diagnostic and/or therapeutic target for cancers, and the 84P2A9 gene or fragment thereof, or its encoded protein or a fragment thereof used to elicit an immune response.
    Type: Application
    Filed: November 7, 2006
    Publication date: March 8, 2007
    Applicant: AGENSYS, INC.
    Inventors: Aya Jakobovits, Daniel Afar, Pia Challita-Eid, Elana Levin, Steve Mitchell, Rene Hubert
  • Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
    Publication number: 20070053921
    Abstract: A novel gene 024P4C12 (also designated 24P4C12) and its encoded protein, and variants thereof, are described wherein 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 24P4C12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 24P4C12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 24P4C12 can be used in active or passive immunization.
    Type: Application
    Filed: September 8, 2006
    Publication date: March 8, 2007
    Inventors: Arthur Raitano, Karen Morrison, Wangmao Ge, Pia Challita-Eid, Aya Jakobovits
  • Nucleic acid and corresponding protein entitled 184P1E2 useful in treatment and detection of cancer
    Publication number: 20070054284
    Abstract: A novel gene (designated 184P1E2) and its encoded protein, and variants thereof, are described wherein 184P1E2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 184P1E2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 184P1E2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 184P1E2 can be used in active or passive immunization.
    Type: Application
    Filed: March 2, 2006
    Publication date: March 8, 2007
    Applicant: Agensys, Inc.
    Inventors: Pia Challita-Eid, Arthur Raitano, Mary Faris, Rene Hubert, Karen Morrison, Robert Morrison, Wangmao Ge, Aya Jakobovits
  • Methods of inducing an immune response
    Publication number: 20070048283
    Abstract: Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene products of a gene of FIG. 2 provide diagnostic, prognostic, prophylactic and/or therapeutic targets for cancer. A gene of FIG. 2 or fragment thereof, its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with a gene product of FIG. 2 can be used in active or passive immunization.
    Type: Application
    Filed: June 15, 2005
    Publication date: March 1, 2007
    Applicant: AGENSYS, INC.
    Inventors: Aya Jakobovits, Pia Challita-Eid, Mary Faris, Wangmao Ge, Rene Hubert, Karen Morrison, Robert Morrison, Arthur Raitano, Daniel Afar
  • Methods of inducing an immune response
    Publication number: 20070048299
    Abstract: Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene products of a gene of FIG. 2 provide diagnostic, prognostic, prophylactic and/or therapeutic targets for cancer. A gene of FIG. 2 or fragment thereof, its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with a gene product of FIG. 2 can be used in active or passive immunization.
    Type: Application
    Filed: June 17, 2005
    Publication date: March 1, 2007
    Applicant: AGENSYS, INC.
    Inventors: Aya Jakobovits, Pia Challita-Eid, Mary Faris, Wangmao Ge, Rene Hubert, Karen Morrison, Robert Morrison, Arthur Raitano, Daniel Afar
  • Methods of inducing an immune response
    Publication number: 20070041968
    Abstract: Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene products of a gene of FIG. 2 provide diagnostic, prognostic, prophylactic and/or therapeutic targets for cancer. A gene of FIG. 2 or fragment thereof, its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with a gene product of FIG. 2 can be used in active or passive immunization.
    Type: Application
    Filed: June 17, 2005
    Publication date: February 22, 2007
    Applicant: AGENSYS, INC.
    Inventors: Aya Jakobovits, Pia Challita-Eid, Mary Faris, Wangmao Ge, Rene Hubert, Karen Morrison, Robert Morrison, Arthur Raitano, Daniel Afar
  • Nucleic acid and corresponding protein entitled 85P1B3 useful in treatment and detection of cancer
    Publication number: 20070036762
    Abstract: A novel gene (designated 85P1B3) and its encoded protein are described. While 85P1B3 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including set forth in Table 1. Consequently, 85P1B3 provides a diagnostic and/or therapeutic target for cancers. The 85P1B3 gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit an immune response.
    Type: Application
    Filed: July 19, 2006
    Publication date: February 15, 2007
    Applicant: AGENSYS, INC.
    Inventors: Arthur Raitano, Mary Faris, Rene Hubert, Daniel Afar, Wangmao Ge, Pia Challita-Eid, Aya Jakobovits
  • Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer
    Publication number: 20070037745
    Abstract: A novel gene (designated 213P1F11) and its encoded protein, and variants thereof, are described wherein 213P1F11 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 213P1F11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 213P1F11 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 213P1F11 can be used in active or passive immunization.
    Type: Application
    Filed: March 25, 2005
    Publication date: February 15, 2007
    Inventors: Pia Challita-Eid, Arthur Raitano, Mary Faris, Rene Hubert, Robert Morrison, Wangmao Ge, Aya Jakobovits
  • Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
    Publication number: 20070031335
    Abstract: Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene products of a gene of FIG. 2 provide diagnostic, prognostic, prophylactic and/or therapeutic targets for cancer. A gene of FIG. 2 or fragment thereof, its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with a gene product of FIG. 2 can be used in active or passive immunization.
    Type: Application
    Filed: April 10, 2002
    Publication date: February 8, 2007
    Inventors: Aya Jakobovits, Pia Challita-Eid, Mary Faris, Wangmao Ge, Rene Hubert, Karen Jane Morrison, Robert Morrison, Arthur Raitano, Daniel Afar
  • 103P2D6: tissue specific protein highly expressed in various cancers
    Patent number: 7172898
    Abstract: A novel gene (designated 103P2D6) and its encoded protein are described. 103P2D6 is not expressed in normal adult tissue, but is highly expressed in prostate tissue xenografts, providing evidence that it is turned on in prostate cancer. 103P2D6 is also expressed in some fetal tissues, and in breast, bladder, lung, bone, colon, pancreatic, testicular, cervical and ovarian cancers. Consequently, 103P2D6 provides a diagnostic and/or therapeutic target for cancers, and the 103P2D6 gene or fragment thereof, or its encoded protein or a fragment thereof can be used to elicit an immune response.
    Type: Grant
    Filed: October 29, 2002
    Date of Patent: February 6, 2007
    Assignee: Agensys, Inc.
    Inventors: Arthur B. Raitano, Daniel E. H. Afar, Gazelle S. Rastegar, Steve Chappell Mitchell, Rene S. Hubert, Pia M. Challita-Eid, Mary Faris, Aya Jakobovits
  • Nucleic acid and corresponding protein entitled 238P1B2 useful in treatment and detection of cancer
    Publication number: 20070015704
    Abstract: A novel gene (designated 238P1B2) and its encoded protein, and variants thereof, are described wherein 238P1B2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 238P1B2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 238P1B2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 238P1B2 can be used in active or passive immunization.
    Type: Application
    Filed: July 6, 2006
    Publication date: January 18, 2007
    Inventors: Arthur Raitano, Pia Challita-Eid, Mary Faris, Rene Hubert, Robert Morrison, Wangmao Ge, Aya Jakobovits
  • Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
    Publication number: 20070004913
    Abstract: A gene (designated 161P2F10B) and its encoded protein are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit a humoral or cellular immune response.
    Type: Application
    Filed: June 2, 2004
    Publication date: January 4, 2007
    Inventors: Pia Challita-Eid, Arthur Raitano, Mary Faris, Rene Hubert, Karen Morrison, Aya Jakobovits
  • C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
    Patent number: 7153940
    Abstract: A novel gene (designated PC-LECTIN) that is highly overexpressed in prostate cancer and its encoded protein is described. PC-LECTIN in normal human tissues is restricted to testis, but is highly expressed in prostate cancer. Consequently, PC-LECTIN provides a diagnostic and/or therapeutic target for prostate cancer.
    Type: Grant
    Filed: June 11, 2003
    Date of Patent: December 26, 2006
    Assignee: Agensys, Inc.
    Inventors: Daniel E. H. Afar, Rene S. Hubert, Aya Jakobovits, Arthur B. Raitano
  • C-type LECTIN transmembrane antigen expressed in human prostate cancer and uses thereof
    Patent number: 7148337
    Abstract: A novel gene (designated PC-LECTIN) that is highly overexpressed in prostate cancer and its encoded protein is described. PC-LECTIN in normal human tissues is restricted to testis, but is highly expressed in prostate cancer. Consequently, PC-LECTIN provides a diagnostic and/or therapeutic target for prostate cancer.
    Type: Grant
    Filed: July 23, 2004
    Date of Patent: December 12, 2006
    Assignee: Agensys, Inc.
    Inventors: Daniel E. H. Afar, Rene S. Hubert, Aya Jakobovits, Arthur B. Raitano
  • Antibodies and related molecules that bind to 161P2F10B proteins
    Publication number: 20060275211
    Abstract: Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.
    Type: Application
    Filed: March 31, 2006
    Publication date: December 7, 2006
    Applicant: Agensys, Inc.
    Inventors: Aya Jakobovits, Steven Kanner, Pia Challita-Eid, Juan Perez-Villar, Daulet Satpaev, Arthur Raitano, Robert Morrison, Karen Morrison, Xiao-Chi Jia, Jean Gudas
  • Production of antibodies using cre-mediated site-specific recombination
    Patent number: 7145056
    Abstract: A method to produce a cell expressing an antibody from a genomic sequence of the cell comprising a modified immunoglobulin locus using Cre-mediated site-specific recombination is disclosed. The method involves first transfecting an antibody-producing cell with a homology-targeting vector comprising a lox site and a targeting sequence homologous to a first DNA sequence adjacent to the region of the immunoglobulin loci of the genomic sequence which is to be converted to a modified region, so the first lox site is inserted into the genomic sequence via site-specific homologous recombination. Then the cell is transfected with a lox-targeting vector comprising a second lox site suitable for Cre-mediated recombination with the integrated lox site and a modifying sequence to convert the region of the immunoglobulin loci to the modified region.
    Type: Grant
    Filed: July 31, 2002
    Date of Patent: December 5, 2006
    Assignees: Abgenix, Inc., Japan Tobacco, Inc.
    Inventors: Aya Jakobovits, Krisztina M. Zsebo
  • Nucleic acid and corresponding protein entitled 184P1E2 useful in treatment and detection of cancer
    Patent number: 7135549
    Abstract: A novel gene (designated 184P1E2) and its encoded protein, and variants thereof, are described wherein 184P1E2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 184P1E2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 184P1E2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 184P1E2 can be used in active or passive immunization.
    Type: Grant
    Filed: April 9, 2002
    Date of Patent: November 14, 2006
    Assignee: Agensys, Inc.
    Inventors: Pia M. Challita-Eid, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Karen Jane Meyrick Morrison, Robert Kendall Morrison, Wangmao Ge, Aya Jakobovits
  • Nucleic acids and corresponding proteins entitled 282P1G3 useful in treatment and detection of cancer
    Patent number: 7115727
    Abstract: A novel gene 282P1G3 and its encoded protein, and variants thereof, are described wherein 282P1G3 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 282P1G3 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 282P1G3 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 282P1G3 can be used in active or passive immunization.
    Type: Grant
    Filed: May 9, 2003
    Date of Patent: October 3, 2006
    Assignee: Agensys, Inc.
    Inventors: Mary Faris, Pia M. Challita-Eid, Aya Jakobovits, Arthur B. Raitano, Wangmao Ge
  • Human monoclonal antibodies to epidermal growth factor receptor
    Publication number: 20060183887
    Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human epidermal growth factor receptor (EGF-r). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences from CDR1 through CDR3, are provided. Hybridomas expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
    Type: Application
    Filed: November 4, 2005
    Publication date: August 17, 2006
    Inventors: Aya Jakobovits, Xiao-Dong Yang, Michael Gallo, Xiao-Chi Jia